공시 • 19h
ZYUS Life Sciences Corporation announced that it has received CAD 0.265 million in funding and other investors. ZYUS Life Sciences Corporation announced that it has raised CAD 265,000 in a round of funding on May 28, 2026. The company received secured Loan in the transaction. 공시 • May 26
ZYUS Life Sciences Corporation, Annual General Meeting, Jul 24, 2026 ZYUS Life Sciences Corporation, Annual General Meeting, Jul 24, 2026. New Risk • May 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$13m). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m (CA$465k revenue, or US$342k). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$40.3m market cap, or US$29.6m). 공시 • Apr 18
Zyus Life Sciences Announces Completion of the Final Study Visit by the Last Patient in Phase 2A Utopia-1 Trial Evaluating Novel Non-Opioid Pain Drug ZYUS Life Sciences Corporation announced that the last patient has completed the final study visit in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating efficacy of Trichomylin softgel capsules in patients experiencing moderate to severe cancer-related pain. UTOPIA-1 trial is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With the completion of the final study visit, the Phase 2a UTOPIA-1 trial has reached the last patient last visit milestone. Top-line results from the Phase 2a UTOPIA-1 trial are expected to be reported in Q2, following completion of data cleaning and analysis. These findings will build on the encouraging preliminary data previously announced that suggested Trichomylin softgel capsules was effective for pain management, safe and well tolerated, and indicated potential for opioid-sparing. 공시 • Feb 25
ZYUS Life Sciences Corporation announced that it expects to receive CAD 7 million in funding ZYUS Life Sciences Corporation announced a non-brokered private placement of 11,111,111 Units of the company at a price of CAD 0.63 for gross proceeds of CAD 7,000,000 on February 24, 2026. Each Unit will consist of one common share of the Company and one-half (1/2) of one Common Share purchase warrant at an exercise price of CAD 0.85 for a period of 24 months from the date of issuance. In connection with the private placement, the Company may pay certain eligible finders a cash fee in respect of the gross proceeds raised under the private placement. 공시 • Jan 12
ZYUS Life Sciences Corporation announced that it expects to receive CAD 16 million in funding ZYUS Life Sciences Corporation announces a brokered private placement of a minimum of 23,809,523 units of the Company and up to a maximum of 25,396,825 Units at a price of CAD 0.63 per Unit for minimum gross proceeds of CAD 15,000,000 and maximum gross proceeds of up to CAD 16,000,000 on January 12, 2026. Each unit will be comprised of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder to purchase one additional Common Share at an exercise price of CAD 0.85 for a period of 24 months from the date of issuance. Closing of the LIFE Offering is expected to occur on or about January 29, 2026, or such other date as the Company and the Lead Agent may agree, subject to receipt of all necessary regulatory approvals, including approval of the TSXV. In Connection with the LIFE Offering, the Company has agreed to pay the Agents a cash commission of 5.0% of the gross proceeds of the LIFE Offering, and to issue Agents’ warrants equal to 5.0% of the number of Units sold under the LIFE Offering, each Agents’ warrant exercisable for one Common Share at the Offering Price for a period of 36 months from the date of issuance. Subscriptions from purchasers on the President’s List up to a maximum of CAD 5,000,000 will be subject to reduced compensation of 2.5% cash commission and 2.5% Agents’ warrants. In addition, the Company will pay the Lead Agent a corporate finance fee consisting of (i) a cash fee equal to 2.0% of the gross proceeds of the LIFE Offering and (ii) corporate finance warrants equal to 2.0% of the number of Units sold under the LIFE Offering, in each case excluding President’s List subscriptions. 공시 • Jan 08
ZYUS Life Sciences Corporation Reports Preliminary Results from Ongoing Phase 2A UTOPIA-1 Trial Evaluating Novel Non-Opioid Pain Drug ZYUS Life Sciences Corporation announced favourable preliminary results from its ongoing Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial evaluating Trichomylin®? softgel capsules in patients experiencing moderate to severe cancer-related pain. Preliminary results Highlights. UTOPIA-1 is a single-arm, proof-of-concept study designed to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Preliminary results from Phase 2a are based on data from the first 25% of enrolled patients who have completed treatment in the UTOPIA-1 trial. Early data suggest a reduction in average daily pain, pain interference, and pain severity; a reduction in opioid dosing for breakthrough pain; and no serious adverse events related to Trichomylin® softgel capsules. Trichomylin® softgel capsules were generally well tolerated, with the majority of adverse reactions being expected, mild, and occurring during dose titration, consistent with the Company's Phase 1 Z-TRI-10001 trial (NCT04867057). Reported Earnings • Nov 29
Third quarter 2025 earnings released: CA$0.046 loss per share (vs CA$0.054 loss in 3Q 2024) Third quarter 2025 results: CA$0.046 loss per share (improved from CA$0.054 loss in 3Q 2024). Net loss: CA$3.62m (loss narrowed 7.5% from 3Q 2024). 공시 • Nov 08
ZYUS Life Sciences Corporation announced that it expects to receive CAD 1.5 million in funding ZYUS Life Sciences Corporation announces 2,307,692 units at a price of CAD 0.65 per Unit for gross proceeds of up to CAD 1,500,000 on November 7, 2025. Each Unit consists of one common share of the Company and one Common Share purchase warrant, whereby each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. No finder's fees were paid in connection with the Offering. All securities issued by way of the First Tranche are subject to a hold period expiring March 7, 2026, in accordance with applicable securities laws and the policies of the TSXV. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV.
On the same day, It has issued 1,923,077 Units at a price of CAD 0.65 for gross proceeds of CAD 1,250,000.05. 공시 • Oct 22
ZYUS Life Sciences Corporation announced that it has received funding On October 20, 2025, The company has closed the transaction. The company has amended the terms of the transaction. The company has issued 724,637 common share purchase warrants at an exercise price of $0.69 per common share until the expiry date. he Loan bears interest at an annual rate of 12%, is payable on maturity, is pre-payable by the Company at any time without penalty or premium and will mature on October 31, 2027. 공시 • Oct 03
Zyus Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2A Utopia-1 Cancer Pain Trial ZYUS Life Sciences Corporation announced the activation of two additional clinical sites in its Phase 2a UTOPIA-1 (Unique Treatment of Oncology Pain in Advanced Cancer) trial. The addition of CancerCare Manitoba ("CCMB") and The Research Institute of the McGill University Health Centre ("The Institute"), along with the Centre Hospitalier de l'Université de Montréal ("CHUM"), expands the Phase 2a UPOPIA-1 trial to three active clinical sites across Canada. UTOPIA-1 is a single-arm, proof-of-concept study designed to evaluate the safety and preliminary analgesic efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. With three active sites, the trial is positioned to broaden diversity of trial participants and accelerate patient enrollment in the Phase 2a UTOPIA-1 trial evaluating Trichomylin softgel capsules. Reported Earnings • Aug 31
Second quarter 2025 earnings released: CA$0.059 loss per share (vs CA$0.068 loss in 2Q 2024) Second quarter 2025 results: CA$0.059 loss per share (improved from CA$0.068 loss in 2Q 2024). Net loss: CA$4.42m (loss narrowed 8.1% from 2Q 2024). 공시 • Jul 31
ZYUS Life Sciences Corporation announced that it expects to receive CAD 1 million in funding ZYUS Life Sciences Corporation announced a non brokered private placement to issue 1,408,450 Units at a price of CAD 0.71 per unit for aggregate gross proceeds of CAD 999,999.5 on July 29, 2025. Each Unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder to acquire one common share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV.
On the same day the company issued 450,281 Units at a price of CAD 0.71 for aggregate proceeds of CAD 319,699.51 in its first tranche. All securities issued in the First Tranche are subject to a hold period expiring November 30, 2025, in accordance with applicable securities laws and the policies of the TSXV. 공시 • Jul 15
ZYUS Life Sciences Corporation Appoints Dr. Julie Stakiw, MD, FRCPC as Chief Medical Officer, Effective July 14, 2025 ZYUS Life Sciences Corporation announced the appointment of Dr. Julie Stakiw, MD, FRCPC, to the Company's leadership team as Chief Medical Officer (CMO), effective July 14, 2025. Dr. Stakiw is a prominent hematologist-oncologist with over two decades of clinical and academic experience based in Saskatoon, Saskatchewan, specializing in blood cancers and stem cell transplantation. As CMO, Dr. Stakiw will provide clinical leadership and oversee the scientific integrity of ZYUS' clinical development program. Her appointment marks a significant step as the Company advances its lead drug product candidate, Trichomylin® softgel capsules, through its pivotal Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) trial. Dr. Stakiw completed her medical degree and internal medicine residency at the University of Saskatchewan, followed by specialized training in hematology at Queen's University and a clinical fellowship in lymphoma and stem cell transplantation at Princess Margaret Hospital in Toronto. She has held several key leadership positions including Provincial Leader of Hematology, Medical Director of Saskatchewan's Blood and Marrow Transplant Program, and Medical Director of the Saskatoon Cancer Clinic. Dr. Stakiw also previously served as Director of Clinical Trials at a regional cancer centre in Ontario and as Director of Patient Research and Innovation for the Saskatchewan Cancer Agency. Known for her patient-centered approach andexpertise in managing complex hematologic conditions such as multiple myeloma and leukemia, Dr. Stakiw continues to serve as a Clinical Professor in Hematological Oncology at the University of Saskatchewan while maintaining an active clinical practice. Her extensive clinical and leadership experience will be instrumental in advancing ZYUS' clinical development program. Dr. Stakiw succeeds Dr. Lionel Marks de Chabris, who is stepping down as CMO and will continue to provide strategic guidance as Chair of the Clinical Research Advisory Committee. The Company is grateful for Dr. Marks de Chabris's ongoing leadership and commitment to advancing ZYUS' mission. 공시 • Jun 29
ZYUS Life Sciences Corporation announced that it has received CAD 0.747899 million in funding On June 27, 2025, ZYUS Life Sciences Corporation closed the transaction. The company issued 746,267 units at an issue price of CAD 0.67 for gross proceeds of CAD 499,998.89 in its second and final tranche. The company issued a total of 1,116,267 units at a price of CAD 0.67 per unit for gross proceeds of CAD 747,898.89 in the offering. No finder’s fees were paid in connection with the offering. All securities issued under the second tranche are subject to a hold period expiring October 28, 2025, in accordance with applicable securities laws and the policies of the TSXV. The offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. Certain insiders of the company participated in the offering and acquired 746,267 units for CAD 499,998.89. The offering was approved by the directors of the company who are independent in respect of the offering and who are not employees of the company. 공시 • Jun 17
ZYUS Life Sciences Corporation announced that it expects to receive CAD 0.749999 million in funding ZYUS Life Sciences Corporation announced a non-brokered private placement to issue 1,119,402 Units of the company at a price of CAD 0.67 for aggregate gross proceed of CAD 749,999.34. Each Unit consists of one common share of the Company and one-half of one Common Share purchase warrant. Each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.95 for a period of twenty-four months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. The transaction is subject to the approval of the TSXV.
On the same date, the company issued 370,000 Units at a price of CAD 0.67 for aggregate gross proceeds of CAD 247,900.00 in its first Tranche. All securities issued under the First Tranche are subject to a hold period expiring October 17, 2025. Board Change • May 28
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Independent Director Charlotte Hepburn is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. 공시 • May 22
Zyus Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug ZYUS Life Sciences Corporation announced it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial. The Phase 2 UTOPIA clinical trial will consist of Phase 2A ("UTOPIA-1") and Phase 2B ("UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin®? softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population. Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025. ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a "strong consensus" supporting cannabinoids for managing cancer-related symptoms. 공시 • May 16
ZYUS Life Sciences Corporation announced that it has received CAD 1.375 million in funding On May 15, 2025, ZYUS Life Sciences Corporation has closed its second and final tranche. The company has issued 871,212 Units at a price of CAD 0.66 per unit for gross proceeds of CAD 574,999.92.The aggregate gross proceeds raised in the Second Tranche and first tranche of the Offering is approximately CAD 1,370,000. The Company issued a total of 2,083,333 Units each priced at CAD 0.66 per Unit in the Offering. Each Unit consists of one common share of the Company and one-half of one Common Share purchase warrant, whereby each Warrant entitles the holder to acquire one Common Share at a price of CAD 0.94 for a period of 24 months from the date of issuance, unless the term of the Warrant is accelerated pursuant to its terms. No finder’s fees were paid in connection with the Offering. The Units were offered by way of private placement pursuant to exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring September 7, 2025 and all securities issued under the Second Tranche are subject to a hold period expiring September 16, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange. The Offering has received conditional approval from the TSXV and remains subject to final acceptance of the TSXV. New Risk • May 06
New major risk - Negative shareholders equity The company has negative equity. Total equity: -CA$5.3m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$5.3m). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (CA$481k revenue, or US$349k). Minor Risk Market cap is less than US$100m (CA$54.3m market cap, or US$39.4m). Reported Earnings • May 06
Full year 2024 earnings released: CA$0.47 loss per share (vs CA$0.76 loss in FY 2023) Full year 2024 results: CA$0.47 loss per share (improved from CA$0.76 loss in FY 2023). Net loss: CA$33.8m (loss narrowed 21% from FY 2023). 공시 • May 01
ZYUS Life Sciences Corporation announced that it expects to receive CAD 2 million in funding ZYUS Life Sciences Corporation announced a non-brokered private placement to issue up to 3,030,303 units at an issue price of CAD 0.66 per unit for the aggregate gross proceeds of CAD 1,999,999.98 on May 1, 2025. Each unit is comprised of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to acquire one common share at a price of CAD 0.94 for a period of twenty-four months from the date of issuance. No finders fees will be paid in connection with the offering. The transaction is expected to close over multiple tranches as the corporation may determine from time to time, with the first tranche expected to close on or about May 6, 2025. The transaction is subject to customary conditions including, but not limited to, receipt of all necessary TSX Venture Exchange , regulatory and other approvals. Securities offered are subject to hold period of four months plus a day from the date of issuance. 공시 • Apr 21
ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2025 ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2025. Reported Earnings • Nov 30
Third quarter 2024 earnings released: CA$0.054 loss per share (vs CA$0.06 loss in 3Q 2023) Third quarter 2024 results: CA$0.054 loss per share (improved from CA$0.06 loss in 3Q 2023). Net loss: CA$3.92m (loss narrowed 6.6% from 3Q 2023). Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. New Risk • Nov 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (CA$428k revenue, or US$306k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Market cap is less than US$100m (CA$55.8m market cap, or US$39.9m). Reported Earnings • Aug 30
Second quarter 2024 earnings released: CA$0.068 loss per share (vs CA$0.31 loss in 2Q 2023) Second quarter 2024 results: CA$0.068 loss per share (improved from CA$0.31 loss in 2Q 2023). Net loss: CA$4.81m (loss narrowed 48% from 2Q 2023). New Risk • Aug 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$19m free cash flow). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (CA$387k revenue, or US$287k). Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Market cap is less than US$100m (CA$66.9m market cap, or US$49.7m). 공시 • Aug 27
ZYUS Life Sciences Corporation announced that it has received CAD 3.334828 million in funding ZYUS Life Sciences Corporation announced a non-brokered private placement of 3,510,345 units at a price of CAD 0.95 per unit for the gross proceeds of CAD 3,334,828 on August 26, 2024. Each unit consists of one common share of the company and one common share purchase warrant, whereby each warrant entitles the holder to acquire one common share at a price of CAD 1.30 for a period of twenty-four months from the date of issuance. Insiders of the company, who are independent directors, purchased 842,103 Units pursuant to the private placement for gross proceeds of CAD 800,000. All securities issued pursuant to the Private Placement are subject to a statutory hold period expiring four months plus a day from the date of issuance in accordance with applicable securities legislation in Canada. The Private Placement remains subject to the final acceptance of TSX Venture Exchange (“TSXV”). 공시 • Jun 05
ZYUS Life Sciences Receives Cannabis Drug License from Health Canada ZYUS Life Sciences Corporation announced that its wholly owned subsidiary, ZYUS Life Sciences Inc., has received a Cannabis Drug License issued pursuant to the Cannabis Act (Canada) and Cannabis Regulations. This license pertains specifically to its processing facility located in Saskatoon, Saskatchewan, which is dedicated to the manufacture of pharmaceutical-grade cannabinoid formulations. Issuance of the Cannabis Drug License compliments ZYUS’ existing standard processing, research, analytical and medical sales licenses and expands the scope of the Company’s license portfolio by enabling ZYUS to manufacture and distribute drugs containing cannabinoids for Health Canada-approved clinical trials in Canada. Advancing Innovation Through Trichomylin Softgel Capsules Phase 2 Clinical Trial: As previously announced, ZYUS intends to launch a Phase 2 Clinical Trial in Canada later this year to assess the preliminary efficacy, safety, and tolerability of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. ZYUS’ receipt of the Cannabis Drug License and compliance with applicable quality guidelines issued by the International Council for Harmonisation and Good Manufacturing Practice standards provides a robust framework respecting the Company’s manufacture of Trichomylin softgel capsules for its Phase 2 Clinical Trial and brings ZYUS one step closer to achieving its goal of obtaining regulatory approval of its proprietary drug product. New Risk • May 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$19m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$19m free cash flow). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m (CA$387k revenue, or US$282k). Minor Risk Market cap is less than US$100m (CA$71.6m market cap, or US$52.2m). Reported Earnings • May 08
Full year 2023 earnings released: CA$0.76 loss per share (vs CA$0.45 loss in FY 2022) Full year 2023 results: CA$0.76 loss per share (further deteriorated from CA$0.45 loss in FY 2022). Net loss: CA$42.6m (loss widened 73% from FY 2022). 공시 • Apr 14
ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2024 ZYUS Life Sciences Corporation, Annual General Meeting, Jun 27, 2024. Agenda: Annual General and Special meeting. 공시 • Feb 02
Zyus Appoints Dr. Hance Clarke as Clinical Advisory Committee ZYUS Life Sciences Corporation announced the appointment of Hance Clarke, MD, PhD, FRCPC to ZYUS Life Sciences Inc.’s Clinical Advisory Committee. Dr. Clarke’s extensive background in healthcare and pain management aligns seamlessly with the committee's mission to provide valuable insights and strategic guidance to ZYUS’ clinical trial programs. Dr. Clarke is internationally recognized for his outstanding contributions to research productivity and advancements in patient care. He holds the positions of Director of Pain Services at the GoodHope Ehlers Danlos Clinic and the Pain Research Unit at Toronto General Hospital. Additionally, he serves as associate professor in the Department of Anesthesiology and Pain Medicine at the University of Toronto. In his capacity as the Knowledge Translation Chair for the University of Toronto Centre for the Study of Pain, Dr. Clarke demonstrates a strong commitment to advancing the understanding and application of pain research. With over 170 peer-reviewed publications to his credit, he currently holds the position of president-elect of the Canadian Pain Society and serves as the president of the Canadian Consortium for the Investigation of Cannabinoids. Dr. Clarke has also played a leading role in educating the Canadian public about pain control, risk factors for chronic opioid use, alternatives to opioids and the need for further studies on understanding the beneficial and adverse effects of cannabis. Being a public champion of evidence-based solutions for the opioid crisis and a national pain and addictions strategist, Dr. Clarke’s appointment aligns with ZYUS’ clinical research initiatives and his influential insights in this field will offer valuable guidance to further enhance ZYUS’ clinical programs. Dr. Clarke joins previously-appointed Advisory Committee members: ZYUS’ Chief Medical Officer, Dr. Lionel Marks de Chabris, Chair of the Committee; Dr. Mary Lynch, Director of Research at the Pain Management Unit at the Queen Elizabeth II Health Sciences Centre; Dr. Cedric Francois, Co-Founder, Chief Executive Officer and President of Apellis Pharmaceuticals; Dr. Alice Zwerling, Assistant Professor in the School of Epidemiology and Public Health in the Faculty of Medicine at the University of Ottawa; and, Ms. Audrey Haukioja, a seasoned executive with over 25 years of experience in the pharmaceutical field, specializing in clinical trials and drug development. New Risk • Jan 09
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$17m free cash flow). Earnings are forecast to decline by an average of 0.6% per year for the foreseeable future. Revenue is less than US$1m (CA$329k revenue, or US$246k). Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$22m net loss next year). Market cap is less than US$100m (CA$63.1m market cap, or US$47.2m). 공시 • Dec 05
ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin®? Softgel Capsules for Advanced Cancer Pain Management ZYUS Life Sciences Corporation announced that it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin®? softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. Transitioning to Phase 2 Clinical Trial for Trichomylin Softgels: Initially planned as a Phase 2a Clinical Trial, ZYUS has made the strategic decision to fast-track and progress directly to a full Phase 2 Clinical Trial following receipt of positive results from its Phase 1, first-in-human clinical trial testing the safety and tolerability of Trichomylin softgel capsules. While a Phase 2a Clinical Trial could have provided preliminary efficacy data for Trichomylin softgels, it would not have generated the data required by regulatory agencies in Canada and the U.S. to formally commence the regulatory drug approval process and, therefore, completion of a Phase 2b clinical trial would have been necessary. In addition to efficiently building shareholder value, ZYUS believes advancing directly to a full Phase 2 Clinical Trial will also reduce the time and cost associated with obtaining regulatory approval of Trichomylin softgel capsules and delivering this important therapeutic to patients in need. Phase 2 Clinical Trial Structure: ZYUS has selected a leading, full-service Canadian contract research organization with extensive clinical trial management experience to conduct its Phase 2 Clinical Trial. ZYUS anticipates the trial will be structured as a double-blinded, placebo-controlled, randomized, multiple dose escalation study that will enroll a total of up to 126 patients with advanced cancer and moderate to severe cancer-related pain. The company plans to recruit patients at six Canadian investigative sites, with patients being randomized at a 1:1 ratio with approximately 63 patients in each arm. New Risk • Dec 04
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$17m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$17m free cash flow). Revenue is less than US$1m (CA$329k revenue, or US$244k). Minor Risk Market cap is less than US$100m (CA$64.3m market cap, or US$47.6m). Reported Earnings • Dec 01
Third quarter 2023 earnings released: CA$0.06 loss per share (vs CA$0.13 loss in 3Q 2022) Third quarter 2023 results: CA$0.06 loss per share (improved from CA$0.13 loss in 3Q 2022). Net loss: CA$4.19m (loss narrowed 43% from 3Q 2022). 공시 • Nov 24
ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels ZYUS Life Sciences Corporation announced receipt of the final clinical study report and positive results respecting its Phase 1, first-in-human (“FIH”) Clinical Trial for its lead drug product candidate, Trichomylin® softgels. 공시 • Oct 25
ZYUS Life Sciences Corporation Appoints Tim Miller as Director of Investor Relations and Capital Markets, Effective November 1, 2023 ZYUS Life Sciences Corporation announced that Tim Miller is joining the Company as Director of Investor Relations and Capital Markets, effective November 1, 2023. Mr. Miller will be based out of the Company’s Toronto office and brings a wealth of knowledge, experience and expertise to his new role with ZYUS, making him a valuable addition to the team. Mr. Miller is a distinguished professional with a Bachelor of Commerce degree from Ryerson University, boasting an impressive track record of nearly two decades as a capital markets executive. His core focus has been Institutional Equity Sales, and his expertise extends across a broad spectrum of clients. These encompass a wide range, from US and Canadian family offices to hedge funds, pension funds, mutual funds, venture capital firms, and private equity investors. Reported Earnings • Sep 04
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: CA$0.28 loss per share (further deteriorated from CA$0.13 loss in 2Q 2022). Net loss: CA$12.0m (loss widened 63% from 2Q 2022). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. 공시 • Sep 02
ZYUS Life Sciences Corporation Obtains Health Canada Security Clearance for New Board Member, Wayne Brownlee and Announces Reconstitution of its Board Committees ZYUS Life Sciences Corporation announced that Wayne Brownlee, who was conditionally appointed to the Company’s Board of Directors on June 28, 2023, has successfully obtained from Health Canada security clearance required to serve as a director of the Corporation pursuant to the Cannabis Act (Canada). With the appointment of Wayne Brownlee taking effect, the Company’s Board of Directors reconstituted its board committees as follows: Audit Committee: John Knowles (Chair), Garnette Weber and Wayne Brownlee. Compensation Committee: Garnette Weber (Chair), Richard Hoyt and Dr. Charlotte Moore Hepburn. Governance and Nominating Committee: Richard Hoyt (Chair), John Knowles, Brent Zettl and Wayne Brownlee. Board Change • Jul 06
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Wayne Brownlee was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 
